Double-Blind, Placebo Controlled, Phase 3 Trial of ZGN-440 (Beloranib) in Obese Subjects With Prader-Willi Syndrome

Stopped early · Phase 3 · Has a placebo group

Conditions studied: Prader-Willi Syndrome, Obesity

In brief

The purpose of this study is to evaluate efficacy and safety of ZGN-440 (beloranib) in obese adolescent and adult subjects with Prader-Willi Syndrome.

Key facts

Study ID
NCT02179151
Run by
Zafgen, Inc.
People needed
108
Starts
2014-09-01
Expected to finish
2016-10-01
Last updated by the study team
2017-01-26

Who can join

Age: 12 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.